In PDAC, low NSUN6 expression is associated with enhanced cancer cell proliferation and decreased sensitivity to chemotherapy, whereas restoring NSUN6 activity inhibits tumor cell proliferation and reduces invasiveness, improving patient outcomes (Yang R. et al., 2021). Here, NSUN6 is linked to neoplasm.